Results 141 to 150 of about 59,836 (222)

Indicators of Suboptimal Treatment Among Patients With Crohn's Disease Treated With Ustekinumab or Risankizumab and Treatment Journey Among Ustekinumab Discontinuers in the United States

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Patients with Crohn's disease (CD) may experience suboptimal response to advanced therapies (ATs), including interleukin (IL)‐12/23 inhibitor ustekinumab and IL‐23 inhibitor risankizumab. In an evolving treatment landscape, this study evaluated indicators of suboptimal treatment with these agents. Methods This retrospective
Freddy Caldera, Maryia Zhdanava, Sumesh Kachroo, Lilian Diaz, Aditi Shah, Fengyi Jiang, Caroline Kerner, Dominic Pilon, Jennifer Seminerio   +8 more
wiley   +1 more source

Characterization of a Large Hispanic Cohort With Inflammatory Bowel Disease Across a 26‐Year Span: The University of Puerto Rico Registry

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims The limited data on ethnic minorities with inflammatory bowel disease (IBD) is a growing concern, given its increasing incidence in Hispanics in the United States and Latin America. Our aim was to describe a large cohort of Hispanics with IBD studied over two decades.
Alondra Soto‐González, Lizzie M. Ramos‐Tollinchi, Claudia Amaya‐Ardila, Paola López‐Marte, Andrea Sánchez‐Velázquez, Karla Feliciano‐Salva, María T. Anca‐Fullana, Patricia Figueroa‐Rodríguez, Esther A. Torres   +8 more
wiley   +1 more source

Management of Refractory and Difficult‐To‐Treat Inflammatory Bowel Disease: An Expert Opinion Review

JCC Plus, Volume 1, Issue 5, September 2026.
This expert opinion offers a practical framework for refractory and difficult‐to‐treat IBD: confirm inflammation objectively, distinguish pharmacologic from structural and functional disease, and then escalate. Across ten clinical questions, the evidence is often limited to case series, and the resulting statements are identified as expert opinion ...
Filiz Akyuz, Oguz Kagan Bakkaloglu, Nalan Gulsen Unal, Ismail Hakki Kalkan, Mehmet Arhan, Ibrahim Hatemi, Taylan Kav, Murat Toruner, Hale Akpinar, Ahmet Tezel, Aykut Ferhat Celik   +10 more
wiley   +1 more source

Association between periodontitis and oral health–related quality of life in patients with systemic conditions: A meta‐analysis

Journal of Periodontology, Volume 97, Issue 9, Page 1990-2002, September 2026.
Abstract Background The objective of this systematic review is to evaluate whether periodontitis is associated with impaired oral health–related quality of life (OHRQoL) in adults with systemic conditions. Methods Five databases were searched to identify observational studies that tested the association between periodontitis (diagnosed by clinical ...
Rafael Vargas Bortolaso, Catiusse Crestani Del' Agnese, Leandro Machado Oliveira, Patricia A. Miguez, Fabricio Batistin Zanatta, Raquel Pippi Antoniazzi   +5 more
wiley   +1 more source

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. [PDF]

Front Pharmacol
Ameer OZ, Temsah R, Alsouss YO, Al-Amoudi R, Khanfar MA, Salman IM.   +5 more
europepmc   +1 more source

National Trends and Risk Factors for Dysphagia After Anterior Cervical Discectomy and Fusion

The Laryngoscope, Volume 136, Issue 9, Page 3918-3931, September 2026.
From 2016 to 2023, inpatient anterior cervical discectomy and fusion (ACDF) volume declined 52.2% while postoperative dysphagia rates increased 11.4% annually. Analysis of 496,425 cases demonstrated that dysphagia risk varied markedly by surgical indication, with cervical diffuse idiopathic skeletal hyperostosis, cervical spine fracture, and ...
Caryn J. Ha, Sraavya G. Anne, Sara Morgan, Fadar Oliver Otite, Kenneth Yan   +4 more
wiley   +1 more source

Severe aplastic anemia as a rare autoimmune complication of ankylosing spondylitis: A rare case report. [PDF]

Medicine (Baltimore)
Alkhen R, Alswij MA, Musleh M, Mohsen Y, ALHusein Q.   +4 more
europepmc   +1 more source

Research Progress on Alleviating Inflammatory Responses by Regulating Macrophage Polarization Using Medicinal and Edible Homologous Traditional Chinese Medicines

Phytochemicals in Food and Medicine, Volume 1, Issue 3, September 2026.
This review summarizes that medicinal and edible homologous TCMs—such as Mongolian milkvetch root, common turmeric rhizome, and Angelica—alleviate chronic inflammatory diseases (IBD, RA, and AS) by inhibiting M1 and promoting M2 macrophage polarization, providing a theoretical basis for inflammation therapy and daily dietary intervention.
Cheng Zhang, Xinyi Liu, Wenlin Chen, Weilin Song, Junjie Cai, Cheng Liang, Jun Shen, Ruoxuan Liu, Yiming Xu, Chunhui Li, Chenghong Li, Yuyuan Wu, Xinyi Li, Chuwen Li, Hongxun Tao, Yuanye Dang   +15 more
wiley   +1 more source

Retroperitoneal Fibrosis following Etanercept for Ankylosing Spondylitis. [PDF]

Mediterr J Rheumatol
Goh SL, Nagra D, Jayasinghe MM, Hassan R, Adas M, Baghaffar M, Khan A, Stathopoulou E, Musa M, Gayed M, Ganguly S, Khan S, Sinha A.   +12 more
europepmc   +1 more source

Comparative Safety Analysis of Targeted Synthetic and Biologic Disease‐Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan

International Journal of Rheumatic Diseases, Volume 29, Issue 9, September 2026.
ABSTRACT Aim To compare risks of malignancy, opportunistic infections, and venous thromboembolism between the targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) and biologic DMARDs (bDMARDs) at the 2nd and 3rd lines of therapy (LOT). Methods We conducted a cohort study using the National Database of Health Insurance Claims (2013–2021).
Shiori Nishimura, Toshitaka Hirano, Soko Setoguchi, Hiroki Matsui, Yoshinori Takeuchi, Yasushi Inoue, Yoshiya Tanaka, Kunihiro Yamaoka, Yoichi Ii, Shintaro Hiro, Masato Hoshi, Naonobu Sugiyama, Yutaka Matsuyama, Hiraku Kumamaru   +13 more
wiley   +1 more source